Contracts › HT942525C0002
HT942525C0002: Dha Sbir Sequential Phase Ii, Proposal No. H2S-0071, Titled: "Developing an Ideal First Use Agent to Prevent Sepsis in Trauma Wounds During Care Under Fire."
Awarded to Altrazeal Life Sciences Inc by Defense Health Agency.
$1.3Mobligated
$1.3Mpotential value
06 June 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | HT942525C0002 |
|---|---|
| Awardee | Altrazeal Life Sciences Inc |
| Awarding agency | Defense Health Agency |
| Awarding office | DEFENSE HEALTH AGENCY |
| NAICS | 541715 Research and Development in the Physical, Engineering, and Life Sciences (Except Nanotechnology and Biotechnology) |
| PSC | AN12 Health R&D Services; Health Care Services; Applied Research |
| Place of performance | TX |
| Offers received | 1 |
| Period of performance | 07 February 2025 to 06 June 2027 |
| Potential end | 06 June 2027 |
| Estimated recompete solicitation | ~Q4 2026 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541715 contracts · All expiring contracts · USASpending record